Last reviewed · How we verify

Stem Cells,Mesenchymal

Ain Shams Maternity Hospital · Phase 3 active Biologic Under review

Stem Cells,Mesenchymal is a Stem cell therapy Biologic drug developed by Ain Shams Maternity Hospital. It is currently in Phase 3 development for Treatment of graft-versus-host disease.

Mesenchymal stem cells are used to modulate the immune system and promote tissue repair.

Mesenchymal stem cells, specifically those derived from bone marrow or stromal vascular fraction, have been studied in clinical trials for various conditions, including uremia, COVID-19, postviral syndrome, dyspnea, and knee osteoarthritis. These cells, or their extracellular vesicles, have been used as interventions in clinical trials, with some studies examining their use in transplantation procedures, such as kidney transplantation.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameStem Cells,Mesenchymal
SponsorAin Shams Maternity Hospital
Drug classStem cell therapy
ModalityBiologic
Therapeutic areaRegenerative medicine
PhasePhase 3

Mechanism of action

Mesenchymal stem cells have anti-inflammatory properties and can differentiate into various cell types to replace damaged tissues. They also secrete factors that promote tissue repair and regeneration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Stem Cells,Mesenchymal

What is Stem Cells,Mesenchymal?

Stem Cells,Mesenchymal is a Stem cell therapy drug developed by Ain Shams Maternity Hospital, indicated for Treatment of graft-versus-host disease.

How does Stem Cells,Mesenchymal work?

Mesenchymal stem cells are used to modulate the immune system and promote tissue repair.

What is Stem Cells,Mesenchymal used for?

Stem Cells,Mesenchymal is indicated for Treatment of graft-versus-host disease.

Who makes Stem Cells,Mesenchymal?

Stem Cells,Mesenchymal is developed by Ain Shams Maternity Hospital (see full Ain Shams Maternity Hospital pipeline at /company/ain-shams-maternity-hospital).

What drug class is Stem Cells,Mesenchymal in?

Stem Cells,Mesenchymal belongs to the Stem cell therapy class. See all Stem cell therapy drugs at /class/stem-cell-therapy.

What development phase is Stem Cells,Mesenchymal in?

Stem Cells,Mesenchymal is in Phase 3.

What are the side effects of Stem Cells,Mesenchymal?

Common side effects of Stem Cells,Mesenchymal include Graft-versus-host disease.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing